ELF4 and prostate carcinoma: In prostate cancer, during T cell receptor activation, KLF4-deficient TAMs inhibit the expression of ELF4 and KLF4, releasing initial CD8+ T cells from quiescence and activating pro-inflammatory and pro-atherosclerotic pathways, leading to CD8+ T cell proliferation and enhanced immune response that suppresses prostate cancer growth (140).